News Summary
The New York State Office of Cannabis Management has filed multiple charges against Omnium Health Inc. for allegedly running an illegal ‘rent-a-license’ scheme. The investigation revealed that Omnium allowed unlicensed operators to rent its facilities for cannabis manufacturing, resulting in the sale of unregulated products. As a consequence, the OCM plans to revoke Omnium’s licenses and is initiating a statewide product recall. This action highlights concerns over consumer safety and regulatory compliance in New York’s cannabis market.
Long Island, New York – The New York State Office of Cannabis Management (OCM) has filed multiple charges against Omnium Health Inc. (doing business as Omnium Canna) for allegedly operating an illegal “rent-a-license” scheme in the cannabis processing sector. The accusations were made public on October 20, 2025, following an investigation that unveiled significant misconduct by the licensed adult-use processor and distributor.
According to OCM, Omnium is accused of “aiding and abetting” unlicensed processing activity through a reverse licensing scheme. Investigators found that the company had entered into contracts with unlicensed operators, allowing these operators to rent Omnium’s facilities for the manufacturing and packaging of cannabis products. This partnership led to the sale of unregulated cannabis products within licensed dispensaries, raising concerns about consumer safety and compliance with state laws.
As a result of these findings, the OCM plans to revoke Omnium’s licenses and prevent the company from applying for future licensing. In addition, the charges against Omnium include seeking civil penalties related to the unreleased revenue generated from the sales of unregulated cannabis products. The OCM has also initiated a statewide recall of all products linked to Omnium, particularly those identified as packaged under “Omnium d/b/a MFused,” which were connected to the illegal operations.
OCM’s Executive Deputy Director, Felicia A. B. Reid, emphasized that Omnium’s actions represent a serious breach of licensing rules, which are designed to ensure transparency and fairness within the legal cannabis market. This regulatory action is part of a wider strategy aimed at safeguarding the integrity of the New York cannabis marketplace and holding violators accountable.
Investigation and Findings
The investigation into Omnium was carried out by the newly established Trade Practices Bureau of the OCM, which focused on examining the company’s records and business practices. Allegations against Omnium include material misrepresentation and failure to disclose significant changes in business operations. In light of these issues, the OCM’s Director of the Trade Practices Bureau, James Rogers, noted that reverse licensing undermines market integrity and the rights of compliant businesses.
The OCM has expressed concerns that the delay in implementing a third-party seed-to-sale tracking system could further open avenues for reverse licensing within New York’s cannabis market. This tracking system is set to be integrated into the adult-use program by December 17, 2025, and its timely implementation is seen as pivotal to maintaining regulatory compliance and market integrity.
Broader Implications
Other cannabis brands currently under scrutiny as part of this investigation include Stiiizy and Grön. Grön has publicly contested allegations of wrongdoing, asserting its full compliance with state regulations. The company has also clarified that its relationship with Omnium was brief and completely in accordance with OCM requirements.
The fallout from the allegations against Omnium raises wider questions about regulatory enforcement in New York’s burgeoning cannabis industry. As the OCM takes steps to address potential misconduct, the ongoing commitment to consumer safety and market integrity remains a top priority.
As New York continues to develop its legal cannabis framework, the OCM’s actions serve as a crucial reminder of the standards expected within the industry. The outcome of this case may have significant implications for other licensed operators and the regulatory environment in the state moving forward.
Deeper Dive: News & Info About This Topic
HERE Resources
New York Regulators Target Omnium Health for Illicit Cannabis Sales
New York Penalizes Omnium Health Over Cannabis Violations
Additional Resources
- The New York Times
- Cannabis Business Times
- Crain’s New York
- GreenState
- News 10
- Wikipedia: Cannabis in New York
- Encyclopedia Britannica: Cannabis
- Google Search: Omnium Canna
- Google Scholar: New York cannabis regulations
- Google News: New York cannabis licensing issues
Author: STAFF HERE NEW YORK WRITER
The NEW YORK STAFF WRITER represents the experienced team at HERENewYork.com, your go-to source for actionable local news and information in New York, the five boroughs, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as New York Fashion Week, Macy's Thanksgiving Day Parade, and Tribeca Film Festival. Our coverage extends to key organizations like the Greater New York Chamber of Commerce and United Way of New York, plus leading businesses in finance and media that power the local economy such as JPMorgan Chase, Goldman Sachs, and Bloomberg. As part of the broader HERE network, including HEREBuffalo.com, we provide comprehensive, credible insights into New York's dynamic landscape.
